Hospira, Inc. (HSP) - Financial and Strategic SWOT Analysis Review by GlobalData

VIEWS: 101 PAGES: 53

More Info
									           Hospira, Inc. (HSP) - Financial and Strategic SWOT Analysis Review

       Reference Code: GDME714FSA                                                                                     Publication Date: MAY 2011

       275 North Field Drive, Dept.          Phone                                                  Revenue
                                                              +1 224 2122000                                           3,917.2 (million USD)
       051M
       Lake Forest, IL                       Fax              +1 224 2123350                        Net Profit         357.20 (million USD)
       60045                                 Website          www.hospira.com                       Employees          14,000
       United States                         Exchange         HSP [New York Stock Exchange]         Industry           Medical Equipment

      Company Overview
       Hospira, Inc. (Hospira) is a global specialty pharmaceutical and medication delivery company. The company develops,
       manufactures and markets products that help improve the safety and effectiveness and reduce the cost of patient care. It offers
       hospital products, manufacturing capabilities and technological solutions for hospitals to improve medication and safety
       management. Hospira also offers one of the broadest portfolios of generic acute care and oncology injectables, integrated
       infusion therapy, as well as medication management solutions. Its operations are spread across the US, Europe, Latin America
       and Asia Pacific. Hospira is headquartered in Illinois, the US.

      Key Executives                                                               SWOT Analysis
                     Name                                   Title                  Hospira, Inc., SWOT Analysis
      Christopher B. Begley                 Chairman                               Strengths                  Weaknesses

      F. Michael Ball                       Chief Executive Officer
                                                                                   Strong Product Development Legal Proceedings
      Irving W. Bailey II                   Lead Director                          Efforts
      Connie R. Curran                      Director                                                                  Product Recalls
                                                                                   Strategic Acquisitions
      Roger W. Hale                         Director
      Source: Annual Report, Company Website, Primary and Secondary Research,
      GlobalData

      Share Data                                                                   Opportunities                     Threats

       Hospira, Inc.                                                               Global Drug Delivery               Overdependence on Third-
       Share Price (USD) as on 10-May-2011                                 56.94   Devices Market                     Party Arrangements

       EPS (USD)                                                            2.11
                                                                                   Biotech Focus                      Cost Containment Pressures
       Market Cap (million USD)                                            9,384

       Enterprise Value (million USD)                                    10,532

       Shares Outstanding (million)                                          168   Source: Annual Report, Company Website, Primary and Secondary
                                                                                   Research, GlobalData
       Source: Annual Report, Company Website, Primary and Secondary Research,
       GlobalData

      Financial Performance                                                        Recent Developments
                                                                                   Mar 07, 2011         Hospira Names Michael Ball As CEO
                                                                                   Feb 02, 2011         Hospira Reports Net Income Of $357.2
                                                                                                        Million In 2010
                                                                                   Jan 24, 2011         TRDX's Subsidiary Receives Approval As
                                                                                                        Distributor For Hospira
                                                                                   Nov 22, 2010         Hospira Names Francois Dubois As
                                                                                                        Senior Vice President Of Quality
                                                                                   Nov 22, 2010         Hospira Appoints Francois Dubois As
                                                                                                        Senior Vice President Of Quality
                                                                                   Source: Annual Report, Company Website, Primary and Secondary
       Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                   Research, GlobalData
       GlobalData




Hospira, Inc. (HSP) - Financial and Strategic SWOT Analysis Review                                                              Reference Code: GDME714FSA

Source : www.globalcompanyintelligence.com                                                                                                          Page 1
      Table of Contents
      Table of Contents........................................................................................................................................................................................................... 2
      List of Tables .................................................................................................................................................................................................................. 4
      List of Figures................................................................................................................................................................................................................. 5
      Section 1 - About the Company ..................................................................................................................................................................................... 6
      Hospira, Inc. - Key Facts ................................................................................................................................................................................................ 6
      Hospira, Inc. - Key Employees....................................................................................................................................................................................... 7
      Hospira, Inc. - Key Employee Biographies..................................................................................................................................................................... 8
      Hospira, Inc. - Major Products and Services................................................................................................................................................................ 10
      Hospira, Inc. - Medical Equipment Pipeline Products Data.......................................................................................................................................... 12
            Hospira, Inc. Pipeline Products by Equipment Type ............................................................................................................................................. 12
      Hospira, Inc. - Pharmaceutical Pipeline Products Data ............................................................................................................................................... 14
            Hospira, Inc., Pipeline Products by Therapy Area ................................................................................................................................................. 14
            Hospira, Inc., Pipeline Products by Development Phase ...................................................................................................................................... 15
      Hospira, Inc. - History................................................................................................................................................................................................... 17
      Hospira, Inc. - Company Statement ............................................................................................................................................................................. 20
      Hospira, Inc. - Locations And Subsidiaries .................................................................................................................................................................. 22
            Head Office............................................................................................................................................................................................................ 22
            Other Locations & Subsidiaries ............................................................................................................................................................................. 22
      Hospira, Inc. - Key Manufacturing Facilities................................................................................................................................................................. 24
      Section 2 – Company Analysis .................................................................................................................................................................................... 25
      Hospira, Inc. - Business Description ............................................................................................................................................................................ 25
            Business Description - Medication Management................................................................................................................................................... 25
                  Medication Management - Overview............................................................................................................................................................... 25
                  Medication Management - Financials ............................................................................................................................................................. 25
                  Medication Management Systems - Technology ............................................................................................................................................ 26
            Business Description - Other Pharmaceuticals ..................................................................................................................................................... 26
                  Other Pharmaceuticals - Overview ................................................................................................................................................................. 26
                  Other Pharmaceuticals - Financials ................................................................................................................................................................ 26
                  Other Pharmaceuticals - Technology.............................................................................................................................................................. 26
            Business Description - Specialty Injectable Pharmaceuticals ............................................................................................................................... 26
                  Specialty Injectable Pharmaceuticals - Overview ........................................................................................................................................... 26
                  Specialty Injectable Pharmaceuticals - Financials .......................................................................................................................................... 27
                  Specialty Injectable Pharmaceuticals - Technology........................................................................................................................................ 27
      Hospira, Inc. - SWOT Analysis..................................................................................................................................................................................... 28
            SWOT Analysis - Overview ................................................................................................................................................................................... 28
            Hospira, Inc. - Strengths ........................................................................................................................................................................................ 28
                  Strength - Strong Product Development Efforts.............................................................................................................................................. 28
                  Strength - Strategic Acquisitions ..................................................................................................................................................................... 28
                  Strength - Broad Product Portfolio .................................................................................................................................................................. 28
            Hospira, Inc. - Weaknesses................................................................................................................................................................................... 29
                  Weakness - Legal Proceedings ...................................................................................................................................................................... 29
                  Weakness - Product Recalls ........................................................................................................................................................................... 29
                  Weakness - FDA Warning Letters................................................................................................................................................................... 29
            Hospira, Inc. - Opportunities .................................................................................................................................................................................. 30
                  Opportunity - Global Drug Delivery Devices Market ....................................................................................................................................... 30
                  Opportunity - Biotech Focus............................................................................................................................................................................ 30
                  Opportunity - Changing Demographics........................................................................................................................................................... 30



Hospira, Inc. (HSP) - Financial and Strategic SWOT Analysis Review                                                                                                                                 Reference Code: GDME714FSA

Source : www.globalcompanyintelligence.com                                                                                                                                                                                                  Page 2
                  Opportunity - Emerging Markets ..................................................................................................................................................................... 31
                  Opportunity - Project Fuel ............................................................................................................................................................................... 31
            Hospira, Inc. - Threats ........................................................................................................................................................................................... 31
                  Threat - Overdependence on Third-Party Arrangements................................................................................................................................ 31
                  Threat - Cost Containment Pressures............................................................................................................................................................. 31
                  Threat - Intense Competition........................................................................................................................................................................... 32
                  Threat - Stringent Governmental Regulations................................................................................................................................................. 32
      Hospira, Inc. - Key Competitors ................................................................................................................................................................................... 33
      Section 3 – Company Financial Ratios ........................................................................................................................................................................ 34
            Financial Ratios - Capital Market Ratios................................................................................................................................................................ 34
            Financial Ratios - Annual Ratios....
								
To top